Leucid Bio
King's College London spinout developing Lateral CAR-T cell therapies for solid tumours, now in a Phase I/IIa trial.
leucid.com ↗Why it's here
Series A reached £18.7M after a £7.2M A1 close in Feb 2025, and its Phase I/IIa AERIAL trial showed disease control at the lowest dose.
source: prnewswire.co.uk- Focus
- CAR-T Therapy
- Founded
- 2014
- Latest round
- Series A1, £7.2M, Feb 2025
- London office
- 3rd Floor, Bermondsey Wing, Guy's Hospital, Southwark SE1 9RTsource: leucid.com
- London presence
- HQsource: leucid.com
- Investors
- 2invest (lead), Epidarex Capital (lead), Vulpes Investment Management (lead), British Business Bank Future Fund, Sofinnova Partnerssource: leucid.com
- Nearest station
- London Bridge, 284 m
- Visas
- Licensed visa sponsor, listed as Leucid Bio Limitedsource: gov.uk
Verified 6 Oct 2026. How we verify · Suggest a fix
For Leucid Bio
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/leucid-bio"><img src="https://londonmempool.co.uk/badge/leucid-bio.svg" alt="Leucid Bio is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.